Clinical Trials Browser

Terminated × Has results × Dasatinib × Clear all

NCT05198843 2025-10-03

Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body

Phase 1/2 Terminated

1 enrolled 5 charts

Anatomic Stage IV Breast Cancer AJCC v8

NCT02420717 2025-06-08

Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia

Phase 2 Terminated

11 enrolled 13 charts

Burkitt Lymphoma

NCT02954523 2024-07-05

Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations

Phase 1/2 Terminated

10 enrolled 15 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04115059 2024-03-21

Dasatinib In Waldenström Macroglobulinemia

Phase 1 Terminated

3 enrolled 13 charts

Waldenstrom Macroglobulinemia

NCT02059265 2023-08-01

Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer

Phase 2 Terminated

35 enrolled 13 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00788125 2023-07-14

Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors

Phase 1/2 Terminated

7 enrolled 9 charts

CNSGastrointestinalGenitourinaryGynecologicLymphoidSarcoma

Familial ependymoma, Ovarian Germ Cell Cancer, Testicular Germ Cell Tumor, Astrocytoma, Burkitt Lymphoma, Carcinoma, Renal Cell, Immunoblastic Lymphadenopathy, Kidney Neoplasms, Liver Neoplasms, Lymphoma, Medulloblastoma, Wilms Tumor, Neuroblastoma, Oligodendroglioma, Ovarian Neoplasms, Recurrence, Sarcoma, Osteosarcoma, Spinal Cord Neoplasms, Teratoma, Testicular Neoplasms, Lymphoma, Large B-Cell, Diffuse, Central Nervous System Neoplasms, Choroid Plexus Neoplasms, Lymphoma, Large-Cell, Anaplastic, Nephroma, Mesoblastic, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor, Optic Nerve Glioma, Lymphoma, Extranodal NK-T-Cell, Dendritic Cell Sarcoma, Interdigitating

NCT04006847 2022-07-01

Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Phase 1/2 Terminated

1 enrolled 5 charts

Other hematologic neoplasm

Leukemia, Myeloid, Chronic-Phase

NCT02720185 2022-06-03

Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR

Phase 2 Terminated

5 enrolled 12 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03041701 2022-04-14

Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma

Phase 1/2 Terminated

14 enrolled 17 charts

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

NCT01876953 2022-03-31

Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia

Phase 1/2 Terminated

20 enrolled 9 charts

Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Myeloid, Acute

NCT01620216 2021-11-04

Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia

Phase 2 Terminated

12 enrolled 12 charts

LymphoidOther hematologic neoplasm

Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02750514 2021-03-22

FRACTION-Lung

Phase 2 Terminated

295 enrolled 21 charts

Advanced Cancer

NCT00780676 2020-09-03

Personalized Treatment Selection for Metastatic Breast Cancer

Phase 2 Terminated

97 enrolled 7 charts

Breast Neoplasms

NCT02819804 2020-02-11

Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Phase 1 Terminated

1 enrolled 7 charts

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00949988 2019-08-14

BMS-CA180105

Phase 1/2 Terminated

3 enrolled 3 charts

LymphoidOther hematologic neoplasm

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00882583 2019-01-09

Dasatinib

Phase 1 Terminated

22 enrolled 8 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT02709083 2018-11-02

Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia

Phase 2 Terminated

7 enrolled 5 charts

MyeloidOther hematologic neoplasm

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00459108 2018-04-19

Dasatinib in Treating Patients With Advanced Liver Cancer That Cannot Be Removed by Surgery

Phase 2 Terminated

25 enrolled 7 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT00860158 2018-03-14

Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer

Phase 2 Terminated

1 enrolled 3 charts

Prostatic Neoplasms

NCT01488318 2018-01-05

Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma

Phase 2 Terminated

21 enrolled 8 charts

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

NCT00538980 2017-06-20

Dasatinib in Polycythemia Vera

Phase 2 Terminated

10 enrolled 7 charts

Polycythemia Vera

NCT01173679 2017-04-14

Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL

Phase 2 Terminated

10 enrolled 6 charts

LymphoidOther hematologic neoplasm

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01357655 2017-03-14

Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)

Phase 2 Terminated

70 enrolled 8 charts

Other hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia

NCT00560352 2017-03-13

Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple Myeloma

Phase 1 Terminated

16 enrolled 15 charts

Multiple Myeloma

NCT00564876 2015-02-23

TOP0706

Phase 2 Terminated

2 enrolled 4 charts

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT00903006 2015-02-02

Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer

Phase 1/2 Terminated

11 enrolled 6 charts

Breast Neoplasms

NCT00918385 2014-10-29

ARS

Phase 2 Terminated

57 enrolled 8 charts

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT01491633 2014-07-15

Dasatinib in Advanced Squamous Cell Lung Cancer

Phase 2 Terminated

5 enrolled 7 charts

Lung Neoplasms

NCT00835679 2014-05-23

Cetuximab and/or Dasatinib in Patients With Colorectal Cancer and Liver Metastases That Can Be Removed by Surgery

Phase EARLY_PHASE1 Terminated

9 enrolled 3 charts

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

NCT00858403 2014-01-15

Dasatinib in Advanced Non-small Cell Lung Cancer (NSCL) With Ex Vivo and In Vivo Assessment of Tumor Target Modulation

Phase 2 Terminated

7 enrolled 7 charts

Lung Neoplasms

NCT00320190 2013-10-30

Study of Dasatinib in Patients With Chronic Phase Chronic Myeloid Leukemia and a Suboptimal Response to Imatinib

Phase 2 Terminated

52 enrolled 8 charts

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT00817531 2012-08-31

Efficacy Study of Dasatinib in Locally Advanced Triple-Negative Breast Cancer Patients

Phase 2 Terminated

22 enrolled 7 charts

Breast Neoplasms

NCT00948389 2012-08-31

Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM)

Phase 1/2 Terminated

28 enrolled 16 charts

Glioblastoma

NCT00362466 2009-11-20

A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy

Phase 3 Terminated

3 enrolled 5 charts

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Chronic-Phase